Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Analysis of ILIT vs SCIT in Grass Pollen Allergy
NCT05960266Phase 1Completed
- Sponsor
- University of Zurich
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Polvac Grass+Rye in seasonal allergic rhinitis (SAR) (2 arms), sponsored by University of Zurich. Primary endpoints: Frequency of treatment-related immune cells in the FNA sample at 24 hours and Frequency of treatment-related immune cells in the blood samples at 28 days. Started Nov 2023; status: completed.
02
Drugs
Polvac Grass+Rye
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05960266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960266.